Novartis Ag (NVS) 92.25 $NVS
Rhabdomyosarcoma Therapeutic Pipeline Review H2 2014 Report at ReportsnReports.com
PRWeb - Sat Jan 03, 11:00AM CST
The report "Rhabdomyosarcoma Pipeline Review, H2 2014" provides comprehensive information on the therapeutic development for Rhabdomyosarcoma. Rhabdomyosarcoma is a cancerous tumor of the muscles that are attached to the bones. It mostly occurs in areas naturally lacking in skeletal muscle such as the head and neck, the urogenital tract, and the arms or legs. The cause of rhabdomyosarcoma is unknown. It is a rare tumor with only several hundred new cases per year in the United States. The most common symptom is a mass that may or may not be painful and other symptoms vary depending on location of the tumor. Complete Report is Available @ http://www.reportsnreports.com/reports/321892...-2014.html .
BLCM: 22.86 (-0.18), GSK: 42.37 (-0.37), NVS: 92.25 (-0.41), CELGZ: 3.15 (unch)
Novartis (NVS) Closes Sale of Animal Health Division to Eli Lilly - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 02, 4:10PM CST
Novartis (NVS) announced today that it has completed the divestment of its Animal Health Division to Eli Lilly and Company (LLY) for approximately $5.4 billion.
ABBV: 65.89 (+0.45), LLY: 70.06 (+1.07), GSK: 42.37 (-0.37), NVS: 92.25 (-0.41)
Cellectis Is Late To The CAR-T Cell Race, But Could Finish First
Intrepid Investor - at Seeking Alpha - Fri Jan 02, 3:21PM CST
BLUE: 91.26 (-0.46), BLCM: 22.86 (-0.18), KITE: 60.61 (+2.94), JUNO: 48.25 (-3.97), GSK: 42.37 (-0.37), NVS: 92.25 (-0.41), CELG: 113.52 (+1.66)
Eli Lilly: The Blockbuster Combination Of Elanco And Novartis' Animal Health
Investing Strategist - at Seeking Alpha - Fri Jan 02, 9:17AM CST
LLY: 70.06 (+1.07), NVS: 92.25 (-0.41)
Chris Katje's Top 10 Stock Picks For 2015
Chris Katje - at Seeking Alpha - Fri Jan 02, 6:43AM CST
HACK: 26.18 (-0.31), NCMI: 13.91 (-0.46), ICON: 33.80 (+0.01), IL: 11.45 (-0.45), IM: 27.34 (-0.30), ICA: 4.79 (-0.13), MPEL: 24.16 (-1.24), SHLO: 15.34 (-0.39), GSK: 42.37 (-0.37), MTW: 21.88 (-0.22), NRG: 27.50 (+0.55), OMAB: 35.50 (-0.84), NVS: 92.25 (-0.41)
Wall Street Breakfast: Euro Slides As Draghi Hints At QE
Wall Street Breakfast - at Seeking Alpha - Fri Jan 02, 5:30AM CST
MPW: 14.04 (+0.26), SIGM: 7.03 (-0.37), AMZN: 308.52 (-1.83), BOND: 107.84 (+0.63), LLY: 70.06 (+1.07), FCAU: 11.69 (+0.11), RBS: 11.93 (-0.18), INTC: 36.36 (+0.07), GOOG: 524.81 (-1.59), SPY: 205.43 (-0.11), QQQ: 102.94 (-0.31), MIXT: 6.38 (-0.12), GM: 34.84 (-0.07), GOOGL: 529.55 (-1.11), HMC: 29.59 (+0.07), NVS: 92.25 (-0.41)
Hypertension - Pipeline Review, H2 2014
M2 - Fri Jan 02, 4:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/hcv5ff/hypertension) has announced the addition of the "Hypertension - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypertension and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hypertension - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hypertension pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Ahn-Gook Pharmaceutical - Beijing Labsolutions Pharmaceuticals - BioLineRx - Biocon Limited - CJ CheilJedang - Chong Kun Dang Pharmaceutical - Compugen - Cytokinetics - Daewoong Pharmaceutical - Daiichi Sankyo Company - DiaMedica - Dong-A Socio - Eli Lilly and Company - GlaxoSmithKline - HanAll Biopharma - IntelGenx - LG Life Sciences - Medivir - Merck & Co - Mitsubishi Tanabe Pharma Corporation - Novartis - Palatin Technologies - Pharmazz - Sanofi - Takeda Pharmaceutical Company - Teva Pharmaceutical Industries - Toray Industries - Torrent Pharmaceuticals - Yuhan Corporation - Yungjin For more information visit http://www.researchandmarkets.com/research/hc...pertension
LLY: 70.06 (+1.07), GSK: 42.37 (-0.37), MRK: 57.19 (+0.40), CGEN: 8.60 (+0.27), PTN: 0.80 (+0.07), TEVA: 56.22 (-1.29), NVS: 92.25 (-0.41)
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H2 2014
M2 - Fri Jan 02, 4:21AM CST
Research and Markets (http://www.researchandmarkets.com/research/2n69ld/relapsing) has announced the addition of the "Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS) and special features on late-stage and discontinued projects Scope - The report provides a snapshot of the global therapeutic landscape of Relapsing Remitting Multiple Sclerosis (RRMS) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Relapsing Remitting Multiple Sclerosis (RRMS) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Relapsing Remitting Multiple Sclerosis (RRMS) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Relapsing Remitting Multiple Sclerosis (RRMS) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned: - F. Hoffmann-La Roche Ltd. - Sanofi - GlaxoSmithKline plc - MedImmune, LLC - XenoPort, Inc. - Novartis AG - Actelion Ltd - Mitsubishi Tanabe Pharma Corporation - Octapharma AG - Teva Pharmaceutical Industries Limited - Genmab A/S - Merck KGaA - Antisense Therapeutics Limited - Opexa Therapeutics - Trophos SA - Allozyne - Amarna Therapeutics - Synthetic Biologics - Cognosci - RedHill Biopharm - Nuron Biotech - Neurotec Pharma SL - BIOCAD - AbbVie Inc. For more information visit http://www.researchandmarkets.com/research/2n69ld/relapsing
GSK: 42.37 (-0.37), XNPT: 8.83 (+0.06), OPXA: 0.77 (+0.05), SYN: 1.55 (+0.09), ABBV: 65.89 (+0.45), TEVA: 56.22 (-1.29), NVS: 92.25 (-0.41)
Osteoporosis - Pipeline Review, H2 2014
M2 - Fri Jan 02, 4:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/smnrjh/osteoporosis) has announced the addition of the "Osteoporosis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Osteoporosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Osteoporosis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Osteoporosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Osteoporosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Abiogen Pharma S.p.A. - Alethia Biotherapeutics - Biodel - Bone Medical - Calzada - Dong Wha Pharma - Dongkook Pharmaceutical - ElexoPharm GmbH - F. Hoffmann-La Roche - Galapagos NV - Glide Pharmaceutical Technologies - IMMD - Immunovo BV - Inbiopro Solutions Pvt. - Kaken Pharmaceutical - Kedem Pharmaceuticals - Lead Discovery Center GmbH - Lupin - Medivir AB - Merck & Co. - Merrion Pharmaceuticals Plc - NeoStem - Novartis AG - Omeros Corporation - Pfizer - PhytoHealth Corporation - Radius Health - Siena Biotech S.p.A. - Sumitomo Dainippon Pharma - TSRL For more information visit http://www.researchandmarkets.com/research/sm...teoporosis
RDUS: 41.21 (+2.30), MRK: 57.19 (+0.40), OMER: 25.01 (+0.23), NVS: 92.25 (-0.41)
Acute Heart Failure - Pipeline Review, H2 2014
M2 - Fri Jan 02, 4:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/4c2c74/acute_heart) has announced the addition of the "Acute Heart Failure - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Acute heart failure, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute heart failure and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Acute heart failure - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Acute heart failure pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Amgen Inc. - Novartis AG - Bayer AG - Trevena, Inc. - PhaseBio Pharmaceuticals, Inc. - Angion Biomedica Corp. - Lee's Pharmaceutical Holdings Limited - Anexon, Inc. - Nyken BV - Capricor Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/4c...cute_heart
TRVN: 5.65 (-0.33), AMGN: 159.89 (+0.60), NVS: 92.25 (-0.41)
Novartis closes $5.4B sale of animal-health business
Seeking Alpha - at Seeking Alpha - Thu Jan 01, 8:27AM CST
LLY: 70.06 (+1.07), NVS: 92.25 (-0.41)
My K.I.S.S. Dividend Portfolio: 4th Quarter 2014 Update And Year-End Review
The Part-time Investor - at Seeking Alpha - Thu Jan 01, 7:17AM CST
ARLP: 43.18 (+0.13), UTX: 115.04 (+0.04), OKE: 49.92 (+0.13), SYY: 39.85 (+0.16), WMT: 85.90 (+0.02), DEO: 112.24 (-1.85), UGI: 38.02 (+0.04), SPY: 205.43 (-0.11), TGT: 75.33 (-0.58), DE: 88.34 (-0.13), MSFT: 46.76 (+0.31), BBL: 42.72 (-0.28), WPZ: 46.19 (+1.44), HRS: 71.62 (-0.20), HAS: 54.97 (-0.02), NSC: 109.15 (-0.46), COP: 68.92 (-0.14), WFC: 54.70 (-0.12), CSX: 35.85 (-0.38), BA: 129.95 (-0.03), TUP: 62.40 (-0.60), CBRL: 138.77 (-1.99), AVA: 35.44 (+0.09), WPC: 70.76 (+0.66), BPL: 76.68 (+1.02), MCD: 93.26 (-0.44), CVX: 112.58 (+0.40), SDY: 78.77 (-0.03), FLIC: 27.39 (-0.98), NVS: 92.25 (-0.41),
77.49 (+0.59), KMI: 42.81 (+0.50), GD: 138.45 (+0.83), GE: 25.06 (-0.21), BDX: 139.86 (+0.70), LMT: 193.31 (+0.74), MDT: 71.88 (-0.32), DLR: 66.41 (+0.11), RTN: 108.61 (+0.44), PTY: 16.34 (+0.44), O: 48.62 (+0.91), WEC: 53.19 (+0.45), PAA: 52.31 (+0.99), PEP: 94.44 (-0.12), JNJ: 104.52 (-0.05), CINF: 51.61 (-0.22), PAYX: 46.24 (+0.07), NUS: 42.24 (-1.46), QCOM: 74.28 (-0.05), NHI: 71.26 (+1.30), APD: 145.43 (+1.20), EMR: 61.79 (+0.06), SO: 49.37 (+0.26), ITW: 94.68 (-0.02), DRI: 58.42 (-0.21), NLY: 11.04 (+0.23), BIP: 42.45 (+0.58), OHI: 40.43 (+1.36), PG: 90.44 (-0.65), AFL: 61.08 (-0.01), LLL: 127.49 (+1.28)
Novartis completes divestment of Animal Health business to Eli Lilly for USD 5.4 billion
Thomson Reuters ONE - Thu Jan 01, 12:00AM CST
Novartis International AG / Novartis completes divestment of Animal Health business to Eli Lilly for USD 5.4 billion . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
LLY: 70.06 (+1.07), NVS: 92.25 (-0.41)
Lilly Finalizes Novartis Animal Health Acquisition
PR Newswire - Thu Jan 01, 12:00AM CST
Eli Lilly and Company (NYSE: LLY) today announced that it has completed the acquisition of Novartis Animal Health, which will further position Lilly's Elanco as a global leader in the animal health industry. The transaction, first announced on April 22, has received clearance under the Hart-Scott-Rodino Antitrust Improvements Act. As part of the approval, certain animal health assets in the U.S. relating to the Sentinel® canine parasiticide franchise will be divested to Virbac, as has been previously announced. All other closing conditions have also been met.
LLY: 70.06 (+1.07), NVS: 92.25 (-0.41)
NeuroDerm Skyrockets on Parkinson's Disease Study Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 31, 2:50PM CST
NeuroDerm (NDRM) announced encouraging top-line data from a phase IIa pharmacokinetic study on its levodopa/carbidopa candidates, ND0612H and ND0612L.
IPXL: 31.80 (+0.12), ABBV: 65.89 (+0.45), NDRM: 12.06 (-1.98), NVS: 92.25 (-0.41)
NeuroDerm Rebounds On Parkinson's Disease Drug Data
at Investor's Business Daily - Tue Dec 30, 11:19AM CST
Recent biotech IPO NeuroDerm (NDRM) on Tuesday bounced back from its flop stock market debut last month after it reported positive midstage trial results for its Parkinson's disease candidate, with shares jumping more than 70%. NeuroDerm said...
IPXL: 31.80 (+0.12), ACOR: 40.51 (-0.36), NVS: 92.25 (-0.41), NDRM: 12.06 (-1.98)
On Winning Track: Complementary Research on Vertex, Ignyta, Novartis, Boeing and TransCanada
PR Newswire - Tue Dec 30, 8:20AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including Vertex (NASDAQ: VRTX), Ignyta (NASDAQ: RXDX), Novartis (NYSE: NVS), Boeing (NYSE: BA), and TransCanada (NYSE: TRP). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
VRTX: 123.07 (+4.27), RXDX: 6.86 (+0.01), TRP: 49.29 (+0.19), BA: 129.95 (-0.03), NVS: 92.25 (-0.41)
Is GlaxoSmithKline plc's Monster Dividend Worth the Risk?
George Budwell, The Motley Fool - Motley Fool - Tue Dec 30, 6:14AM CST
Source: GlaxoSmithKline British Pharma giant GlaxoSmithKline has had an awful 2014 by any measure. Over the course of the year, this healthcare stalwart saw payers in the U.S. reject preferred reimbursement status for its next-generation...
PFE: 31.33 (+0.18), GSK: 42.37 (-0.37), NVS: 92.25 (-0.41)
Could These Tiny Biotech Stocks Double in 2015?
Todd Campbell, The Motley Fool - Motley Fool - Tue Dec 30, 5:50AM CST
Biotechnology's mind-numbing share price volatility means that only the most risk-tolerant investors should consider owning them -- but for investors with a penchant for risk and a stomach tough enough to handle the inevitable pops and drops, there...
PTLA: 28.51 (+0.19), GILD: 94.91 (+0.65), ACHN: 13.33 (+1.08), PFE: 31.33 (+0.18), OPHT: 45.60 (+0.73), BMY: 59.51 (+0.48), REGN: 410.16 (-0.09), NVS: 92.25 (-0.41)
Diphtheria - Pipeline Review, H1 2014
M2 - Tue Dec 30, 5:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/c76242/diphtheria) has announced the addition of the "Diphtheria - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Diphtheria, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diphtheria and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Diphtheria - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Diphtheria pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Beijing Minhai Biotechnology Co., Ltd - Biological E. Limited - GlaxoSmithKline plc - Green Cross Corporation - Indian Immunologicals Limited - LG Life Sciences, Ltd. - Novartis AG - Panacea Biotec Limited - Sanofi - Sanofi Pasteur SA - Serum Institute of India Limited - Sinovac Biotech Ltd. - Takeda Pharmaceutical Company Limited - Zydus Cadila Healthcare Limited For more information visit http://www.researchandmarkets.com/research/c76242/diphtheria
GSK: 42.37 (-0.37), SVA: 5.30 (+0.07), NVS: 92.25 (-0.41)
Rhabdomyosarcoma Therapeutic Pipeline Review H2 2014 Report at ReportsnReports.com
PRWeb - Sat Jan 03, 11:00AM CST
The report "Rhabdomyosarcoma Pipeline Review, H2 2014" provides comprehensive information on the therapeutic development for Rhabdomyosarcoma. Rhabdomyosarcoma is a cancerous tumor of the muscles that are attached to the bones. It mostly occurs in areas naturally lacking in skeletal muscle such as the head and neck, the urogenital tract, and the arms or legs. The cause of rhabdomyosarcoma is unknown. It is a rare tumor with only several hundred new cases per year in the United States. The most common symptom is a mass that may or may not be painful and other symptoms vary depending on location of the tumor. Complete Report is Available @ http://www.reportsnreports.com/reports/321892...-2014.html .
BLCM: 22.86 (-0.18), GSK: 42.37 (-0.37), NVS: 92.25 (-0.41), CELGZ: 3.15 (unch)
Novartis (NVS) Closes Sale of Animal Health Division to Eli Lilly - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 02, 4:10PM CST
Novartis (NVS) announced today that it has completed the divestment of its Animal Health Division to Eli Lilly and Company (LLY) for approximately $5.4 billion.
ABBV: 65.89 (+0.45), LLY: 70.06 (+1.07), GSK: 42.37 (-0.37), NVS: 92.25 (-0.41)
Cellectis Is Late To The CAR-T Cell Race, But Could Finish First
Intrepid Investor - at Seeking Alpha - Fri Jan 02, 3:21PM CST
BLUE: 91.26 (-0.46), BLCM: 22.86 (-0.18), KITE: 60.61 (+2.94), JUNO: 48.25 (-3.97), GSK: 42.37 (-0.37), NVS: 92.25 (-0.41), CELG: 113.52 (+1.66)
Eli Lilly: The Blockbuster Combination Of Elanco And Novartis' Animal Health
Investing Strategist - at Seeking Alpha - Fri Jan 02, 9:17AM CST
LLY: 70.06 (+1.07), NVS: 92.25 (-0.41)
Chris Katje's Top 10 Stock Picks For 2015
Chris Katje - at Seeking Alpha - Fri Jan 02, 6:43AM CST
HACK: 26.18 (-0.31), NCMI: 13.91 (-0.46), ICON: 33.80 (+0.01), IL: 11.45 (-0.45), IM: 27.34 (-0.30), ICA: 4.79 (-0.13), MPEL: 24.16 (-1.24), SHLO: 15.34 (-0.39), GSK: 42.37 (-0.37), MTW: 21.88 (-0.22), NRG: 27.50 (+0.55), OMAB: 35.50 (-0.84), NVS: 92.25 (-0.41)
Wall Street Breakfast: Euro Slides As Draghi Hints At QE
Wall Street Breakfast - at Seeking Alpha - Fri Jan 02, 5:30AM CST
MPW: 14.04 (+0.26), SIGM: 7.03 (-0.37), AMZN: 308.52 (-1.83), BOND: 107.84 (+0.63), LLY: 70.06 (+1.07), FCAU: 11.69 (+0.11), RBS: 11.93 (-0.18), INTC: 36.36 (+0.07), GOOG: 524.81 (-1.59), SPY: 205.43 (-0.11), QQQ: 102.94 (-0.31), MIXT: 6.38 (-0.12), GM: 34.84 (-0.07), GOOGL: 529.55 (-1.11), HMC: 29.59 (+0.07), NVS: 92.25 (-0.41)
Hypertension - Pipeline Review, H2 2014
M2 - Fri Jan 02, 4:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/hcv5ff/hypertension) has announced the addition of the "Hypertension - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypertension and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hypertension - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hypertension pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Ahn-Gook Pharmaceutical - Beijing Labsolutions Pharmaceuticals - BioLineRx - Biocon Limited - CJ CheilJedang - Chong Kun Dang Pharmaceutical - Compugen - Cytokinetics - Daewoong Pharmaceutical - Daiichi Sankyo Company - DiaMedica - Dong-A Socio - Eli Lilly and Company - GlaxoSmithKline - HanAll Biopharma - IntelGenx - LG Life Sciences - Medivir - Merck & Co - Mitsubishi Tanabe Pharma Corporation - Novartis - Palatin Technologies - Pharmazz - Sanofi - Takeda Pharmaceutical Company - Teva Pharmaceutical Industries - Toray Industries - Torrent Pharmaceuticals - Yuhan Corporation - Yungjin For more information visit http://www.researchandmarkets.com/research/hc...pertension
LLY: 70.06 (+1.07), GSK: 42.37 (-0.37), MRK: 57.19 (+0.40), CGEN: 8.60 (+0.27), PTN: 0.80 (+0.07), TEVA: 56.22 (-1.29), NVS: 92.25 (-0.41)
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H2 2014
M2 - Fri Jan 02, 4:21AM CST
Research and Markets (http://www.researchandmarkets.com/research/2n69ld/relapsing) has announced the addition of the "Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS) and special features on late-stage and discontinued projects Scope - The report provides a snapshot of the global therapeutic landscape of Relapsing Remitting Multiple Sclerosis (RRMS) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Relapsing Remitting Multiple Sclerosis (RRMS) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Relapsing Remitting Multiple Sclerosis (RRMS) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Relapsing Remitting Multiple Sclerosis (RRMS) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned: - F. Hoffmann-La Roche Ltd. - Sanofi - GlaxoSmithKline plc - MedImmune, LLC - XenoPort, Inc. - Novartis AG - Actelion Ltd - Mitsubishi Tanabe Pharma Corporation - Octapharma AG - Teva Pharmaceutical Industries Limited - Genmab A/S - Merck KGaA - Antisense Therapeutics Limited - Opexa Therapeutics - Trophos SA - Allozyne - Amarna Therapeutics - Synthetic Biologics - Cognosci - RedHill Biopharm - Nuron Biotech - Neurotec Pharma SL - BIOCAD - AbbVie Inc. For more information visit http://www.researchandmarkets.com/research/2n69ld/relapsing
GSK: 42.37 (-0.37), XNPT: 8.83 (+0.06), OPXA: 0.77 (+0.05), SYN: 1.55 (+0.09), ABBV: 65.89 (+0.45), TEVA: 56.22 (-1.29), NVS: 92.25 (-0.41)
Osteoporosis - Pipeline Review, H2 2014
M2 - Fri Jan 02, 4:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/smnrjh/osteoporosis) has announced the addition of the "Osteoporosis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Osteoporosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Osteoporosis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Osteoporosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Osteoporosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Abiogen Pharma S.p.A. - Alethia Biotherapeutics - Biodel - Bone Medical - Calzada - Dong Wha Pharma - Dongkook Pharmaceutical - ElexoPharm GmbH - F. Hoffmann-La Roche - Galapagos NV - Glide Pharmaceutical Technologies - IMMD - Immunovo BV - Inbiopro Solutions Pvt. - Kaken Pharmaceutical - Kedem Pharmaceuticals - Lead Discovery Center GmbH - Lupin - Medivir AB - Merck & Co. - Merrion Pharmaceuticals Plc - NeoStem - Novartis AG - Omeros Corporation - Pfizer - PhytoHealth Corporation - Radius Health - Siena Biotech S.p.A. - Sumitomo Dainippon Pharma - TSRL For more information visit http://www.researchandmarkets.com/research/sm...teoporosis
RDUS: 41.21 (+2.30), MRK: 57.19 (+0.40), OMER: 25.01 (+0.23), NVS: 92.25 (-0.41)
Acute Heart Failure - Pipeline Review, H2 2014
M2 - Fri Jan 02, 4:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/4c2c74/acute_heart) has announced the addition of the "Acute Heart Failure - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Acute heart failure, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute heart failure and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Acute heart failure - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Acute heart failure pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Amgen Inc. - Novartis AG - Bayer AG - Trevena, Inc. - PhaseBio Pharmaceuticals, Inc. - Angion Biomedica Corp. - Lee's Pharmaceutical Holdings Limited - Anexon, Inc. - Nyken BV - Capricor Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/4c...cute_heart
TRVN: 5.65 (-0.33), AMGN: 159.89 (+0.60), NVS: 92.25 (-0.41)
Novartis closes $5.4B sale of animal-health business
Seeking Alpha - at Seeking Alpha - Thu Jan 01, 8:27AM CST
LLY: 70.06 (+1.07), NVS: 92.25 (-0.41)
My K.I.S.S. Dividend Portfolio: 4th Quarter 2014 Update And Year-End Review
The Part-time Investor - at Seeking Alpha - Thu Jan 01, 7:17AM CST
ARLP: 43.18 (+0.13), UTX: 115.04 (+0.04), OKE: 49.92 (+0.13), SYY: 39.85 (+0.16), WMT: 85.90 (+0.02), DEO: 112.24 (-1.85), UGI: 38.02 (+0.04), SPY: 205.43 (-0.11), TGT: 75.33 (-0.58), DE: 88.34 (-0.13), MSFT: 46.76 (+0.31), BBL: 42.72 (-0.28), WPZ: 46.19 (+1.44), HRS: 71.62 (-0.20), HAS: 54.97 (-0.02), NSC: 109.15 (-0.46), COP: 68.92 (-0.14), WFC: 54.70 (-0.12), CSX: 35.85 (-0.38), BA: 129.95 (-0.03), TUP: 62.40 (-0.60), CBRL: 138.77 (-1.99), AVA: 35.44 (+0.09), WPC: 70.76 (+0.66), BPL: 76.68 (+1.02), MCD: 93.26 (-0.44), CVX: 112.58 (+0.40), SDY: 78.77 (-0.03), FLIC: 27.39 (-0.98), NVS: 92.25 (-0.41),
77.49 (+0.59), KMI: 42.81 (+0.50), GD: 138.45 (+0.83), GE: 25.06 (-0.21), BDX: 139.86 (+0.70), LMT: 193.31 (+0.74), MDT: 71.88 (-0.32), DLR: 66.41 (+0.11), RTN: 108.61 (+0.44), PTY: 16.34 (+0.44), O: 48.62 (+0.91), WEC: 53.19 (+0.45), PAA: 52.31 (+0.99), PEP: 94.44 (-0.12), JNJ: 104.52 (-0.05), CINF: 51.61 (-0.22), PAYX: 46.24 (+0.07), NUS: 42.24 (-1.46), QCOM: 74.28 (-0.05), NHI: 71.26 (+1.30), APD: 145.43 (+1.20), EMR: 61.79 (+0.06), SO: 49.37 (+0.26), ITW: 94.68 (-0.02), DRI: 58.42 (-0.21), NLY: 11.04 (+0.23), BIP: 42.45 (+0.58), OHI: 40.43 (+1.36), PG: 90.44 (-0.65), AFL: 61.08 (-0.01), LLL: 127.49 (+1.28) Novartis completes divestment of Animal Health business to Eli Lilly for USD 5.4 billion
Thomson Reuters ONE - Thu Jan 01, 12:00AM CST
Novartis International AG / Novartis completes divestment of Animal Health business to Eli Lilly for USD 5.4 billion . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
LLY: 70.06 (+1.07), NVS: 92.25 (-0.41)
Lilly Finalizes Novartis Animal Health Acquisition
PR Newswire - Thu Jan 01, 12:00AM CST
Eli Lilly and Company (NYSE: LLY) today announced that it has completed the acquisition of Novartis Animal Health, which will further position Lilly's Elanco as a global leader in the animal health industry. The transaction, first announced on April 22, has received clearance under the Hart-Scott-Rodino Antitrust Improvements Act. As part of the approval, certain animal health assets in the U.S. relating to the Sentinel® canine parasiticide franchise will be divested to Virbac, as has been previously announced. All other closing conditions have also been met.
LLY: 70.06 (+1.07), NVS: 92.25 (-0.41)
NeuroDerm Skyrockets on Parkinson's Disease Study Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 31, 2:50PM CST
NeuroDerm (NDRM) announced encouraging top-line data from a phase IIa pharmacokinetic study on its levodopa/carbidopa candidates, ND0612H and ND0612L.
IPXL: 31.80 (+0.12), ABBV: 65.89 (+0.45), NDRM: 12.06 (-1.98), NVS: 92.25 (-0.41)
NeuroDerm Rebounds On Parkinson's Disease Drug Data
at Investor's Business Daily - Tue Dec 30, 11:19AM CST
Recent biotech IPO NeuroDerm (NDRM) on Tuesday bounced back from its flop stock market debut last month after it reported positive midstage trial results for its Parkinson's disease candidate, with shares jumping more than 70%. NeuroDerm said...
IPXL: 31.80 (+0.12), ACOR: 40.51 (-0.36), NVS: 92.25 (-0.41), NDRM: 12.06 (-1.98)
On Winning Track: Complementary Research on Vertex, Ignyta, Novartis, Boeing and TransCanada
PR Newswire - Tue Dec 30, 8:20AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including Vertex (NASDAQ: VRTX), Ignyta (NASDAQ: RXDX), Novartis (NYSE: NVS), Boeing (NYSE: BA), and TransCanada (NYSE: TRP). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
VRTX: 123.07 (+4.27), RXDX: 6.86 (+0.01), TRP: 49.29 (+0.19), BA: 129.95 (-0.03), NVS: 92.25 (-0.41)
Is GlaxoSmithKline plc's Monster Dividend Worth the Risk?
George Budwell, The Motley Fool - Motley Fool - Tue Dec 30, 6:14AM CST
Source: GlaxoSmithKline British Pharma giant GlaxoSmithKline has had an awful 2014 by any measure. Over the course of the year, this healthcare stalwart saw payers in the U.S. reject preferred reimbursement status for its next-generation...
PFE: 31.33 (+0.18), GSK: 42.37 (-0.37), NVS: 92.25 (-0.41)
Could These Tiny Biotech Stocks Double in 2015?
Todd Campbell, The Motley Fool - Motley Fool - Tue Dec 30, 5:50AM CST
Biotechnology's mind-numbing share price volatility means that only the most risk-tolerant investors should consider owning them -- but for investors with a penchant for risk and a stomach tough enough to handle the inevitable pops and drops, there...
PTLA: 28.51 (+0.19), GILD: 94.91 (+0.65), ACHN: 13.33 (+1.08), PFE: 31.33 (+0.18), OPHT: 45.60 (+0.73), BMY: 59.51 (+0.48), REGN: 410.16 (-0.09), NVS: 92.25 (-0.41)
Diphtheria - Pipeline Review, H1 2014
M2 - Tue Dec 30, 5:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/c76242/diphtheria) has announced the addition of the "Diphtheria - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Diphtheria, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diphtheria and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Diphtheria - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Diphtheria pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Beijing Minhai Biotechnology Co., Ltd - Biological E. Limited - GlaxoSmithKline plc - Green Cross Corporation - Indian Immunologicals Limited - LG Life Sciences, Ltd. - Novartis AG - Panacea Biotec Limited - Sanofi - Sanofi Pasteur SA - Serum Institute of India Limited - Sinovac Biotech Ltd. - Takeda Pharmaceutical Company Limited - Zydus Cadila Healthcare Limited For more information visit http://www.researchandmarkets.com/research/c76242/diphtheria
GSK: 42.37 (-0.37), SVA: 5.30 (+0.07), NVS: 92.25 (-0.41)
